Compare WILC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | ALT |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.3M | 415.3M |
| IPO Year | 1997 | N/A |
| Metric | WILC | ALT |
|---|---|---|
| Price | $28.60 | $4.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 10.8K | ★ 5.2M |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $180,746,882.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $12.54 | $2.90 |
| 52 Week High | $31.16 | $7.73 |
| Indicator | WILC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 46.05 |
| Support Level | $27.66 | $4.47 |
| Resistance Level | $29.31 | $4.75 |
| Average True Range (ATR) | 0.97 | 0.41 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 34.73 | 7.14 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.